This thesis is an analysis of factors influencing the technological innovation in the pharmaceutical industry in Korea. The objective of this study is to show that those firms can create more efficiently the technological innovation with improvement of research methodology in future.
For the analysis, the R＆D capabilities, the barriers/facilitators for R＆D and the management support for R＆D are introduced as the independent variables; the technological innovation as the dependent variables. For the analysis of R＆D capabilities, in particular, the R＆D results and the import of technology are introduced as the intervening variables between R＆D capabilities and technological innovation.
In fact, in analyzing the relations between independent variables and dependent variable, the technological innovation is confined to the new product/process as the operational definition, R＆D capabilities to R＆D budget, R＆D results to R＆D project performed, import of technology to number of contracts for technology-import. And variables selected as the R＆D barriers are the laws and regulations of the government, the cost, the low-technology-level, the marketability, the field experiment, the investment basis production change, the raw material and the unavailability of information. Variables selected as the R＆D facilitators are the laws and regulations of the government, the problems occurred in the products and the process, the marketability, the cost and the raw material. Variables selected as the management support for R＆D are the management support for R＆D are the management support for researchers and R＆D activities.
This study has been carried out through the field study building a static model: the data for this study were collected from the R＆D departments of eleven pharmaceutical firms selected by sampling method.
By analyzing the relations between the independent variables and the dependent variables, the following results were obtained: it is accepted as a hypothesis that the company with more R＆D capabilities creates more technological innovations (P＜0.05). But the correlations between R＆D capabilities and R＆D results, between R＆D capabilities and import of technology, between R＆D outcomes and technological innovation, and between import of technology and technological innovation are not significant. From these results, it may be accepted that the policy to aim at the short-term marketability like immitations and the continuing product-development-policy coexist in the R＆D of the Korean pharmaceutical industry.
And there are no significance in the correlations between the barriers/facilitators for R＆D and technological innovation and between the management support for R＆D and the technological innovation.
However, many weak points still remain because this study was processed with a static model not with a dynamic model.
For the future dynamic analysis in the developing countries like Korea, it may be suggested that the production units should be devided into several homogeneous groups based on the rate of technological innovation and based on the type of the technological sources.
